1. 169 Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through three years: long-term data from the FUTURE 1 and FUTURE 2 studies. (25th April 2018) Authors: Chinoy, Hector; Gossec, Laure; Kvien, Tore K; Conaghan, Philip G; Østergaard, Mikkel; Gladman, Dafna; Mease, Philip; Rasouliyan, Lawrence; Pricop, Luminita; Gaillez, Corine; Jugl, Steffen Journal: Rheumatology Issue: Volume 57(2018)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 171 Secukinumab provides sustained PASDAS related low disease activity in psoriatic arthritis: two year results from the FUTURE 2 study. (25th April 2018) Authors: Coates, Laura C; Gladman, Dafna; Nash, Peter; Fitzgerald, Oliver; Kavanaugh, Arthur; Rasouliyan, Lawrence; Pricop, Luminita; Ding, Kevin; Gaillez, Corine Journal: Rheumatology Issue: Volume 57(2018)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 175 Comparative effectiveness of secukinumab and infliximab in psoriatic arthritis assessed by matching-adjusted indirect comparison using pivotal Phase III clinical trial data. (25th April 2018) Authors: Kaul, Arvind; Strand, Vibeke; McInnes, Iain; Mease, Philip; Choy, Ernest; Nash, Peter; Thom, Howard; Kalyvas, Chrysostomos; Gandhi, Kunal; Pricop, Luminita; Jugl, Steffen Journal: Rheumatology Issue: Volume 57(2018)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 184 Secukinumab provides sustained remission and low disease activity related to disease activity index for psoriatic arthritis: two year results from the FUTURE 2 study. (25th April 2018) Authors: McInnes, Iain; Smolen, Josef S; Kvien, Tore K; Pricop, Luminita; Fox, Todd; Rasouliyan, Lawrence; Jugl, Steffen; Gaillez, Corine Journal: Rheumatology Issue: Volume 57(2018)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 185 Secukinumab demonstrates consistent safety over long-term exposure in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses. (25th April 2018) Authors: McInnes, Iain; Mease, Philip; Reich, Kristian; Nash, Peter; Andersson, Mats; Abrams, Ken; Pricop, Luminita; Fox, Todd Journal: Rheumatology Issue: Volume 57(2018)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 254 Impact of secukinumab treatment on psoriatic arthritis patients with or without enthesitis at baseline: pooled data from FUTURE 2 AND FUTURE 3 Phase 3 studies. (12th April 2019) Authors: McInnes, Iain B; Wallman, Johan K; Schett, Georg; Quebe-Fehling, Erhard; Rasouliyan, Lawrence; Pricop, Luminita; Fasth, Andreas E; Gaillez, Corine Journal: Rheumatology Issue: Volume 58(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 256 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 4-year results from the Phase 3 FUTURE 2 study. (12th April 2019) Authors: McInnes, Iain B; Kirkham, Bruce; Nash, Peter; Rahman, Proton; Gottlieb, Alice B; Ding, Kevin; Pricop, Luminita Journal: Rheumatology Issue: Volume 58(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 258 Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5-year efficacy and safety results from the FUTURE 1 Phase 3 trial. (12th April 2019) Authors: Tahir, Hasan; Mease, Philip J; Kavanaugh, Arthur; Reimold, Andreas; Rech, Jürgen; Hall, Stephen; Geusens, Piet; Pellet, Pascale; Delicha, Eumorphia Maria; Pricop, Luminita; Mpofu, Shephard Journal: Rheumatology Issue: Volume 58(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 263 Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52week treatment period. (12th April 2019) Authors: McInnes, Iain B; Deodhar, Atul; Gladman, Dafna D; Ren, Mengyuan; Spindeldreher, Sebastian; Pricop, Luminita; Porter, Brian; Safi, Jorge; Shete, Abhijit; Bruin, Gerard Journal: Rheumatology Issue: Volume 58(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. AB0782 SECUKINUMAB PROVIDES IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS, REGARDLESS OF THE TIME SINCE DIAGNOSIS: POOLED RESULTS FROM THE SECUKINUMAB PHASE 3 TRIAL PROGRAM. (June 2019) Authors: Strand, Vibeke; Fitzgerald, Oliver; Coates, Laura C.; Walsh, Jessica a.; Cañete, Juan D.; Nash, Peter; Davenport, Eric; Pricop, Luminita; Hustache, Gregory; Gilloteau, Isabelle; Yocolly, Aurore; Augustin, Matthias Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 1860 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗